Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab results ...

Please provide your email address to receive an email when new articles are posted on . The AZALEA-TIMI 71 trial stopped early due to an unprecedented bleeding benefit for adults with atrial ...

The novel factor XI/XIa inhibitor abelacimab, being studied in the AZALEA-TIMI 71 trial, lowered a composite of major and clinically relevant nonmajor bleeding compared with rivaroxaban in patients ...

In patients with AF, abelacimab, compared with rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. Abelacimab is associated with reduced bleeding compared with ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation. Study: ...

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today ...

The proof-of-concept study helps "support the notion that you can dissociate antithrombotic effects from potential hemorrhagic effects with a factor XI target strategy," said senior author Jeffrey ...

Please provide your email address to receive an email when new articles are posted on . A single IV dose of the factor XI monoclonal antibody abelacimab appeared superior to daily enoxaparin for ...

Abelacimab, an experimental anti-clotting drug, was effective at lowering bleeding in people with atrial fibrillation (A-Fib) who were at risk of having a stroke compared with a competing drug, ...

Abelacimab reduces major and minor bleeding compared with rivaroxaban for atrial fibrillation -- even in patients with reduced kidney function receiving DOAC dose adjustment. Abelacimab, an ...

A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers. A potentially game-changing treatment for people ...

A phase 2 trial of the investigational factor XI inhibitor, abelacimab, in patients with atrial fibrillation (AF) who are at moderate to high risk for stroke has been stopped early due to "an ...